GlobeNewswire Inc.··Autolus Therapeutics PlcAutolus Therapeutics Posts $74.3M Revenue as AUCATZYL Scales Across Europe
Autolus Therapeutics reported $74.3M in 2025 AUCATZYL revenue with UK launch underway. Company projects $120-135M in 2026 revenue and positive gross margin expansion.
AUTLFDA approvalclinical trials